CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 37 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02038764
NCT02038764Phase 1Completed
CompareCT.gov

A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Adults With Type 1 Diabetes

Pfizer·interventional·Posted Jan 17, 2014·Updated Aug 3, 2018

In Brief

A Phase 1 clinical trial evaluating Placebo, PF-06342674 Dose A, and 3 other interventions for Diabetes Mellitus, Type 1. Completed, enrolled 37 participants across 21 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 17, 2014
Enrollment StartJun 4, 2014
Primary CompletionSep 13, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.5 years ago

Interventions

Placebodrug

Placebo

PF-06342674 Dose Abiological

Multiple SC Doses

PF-06342674 Dose Bbiological

Multiple SC Doses

PF-06342674 Dose Cbiological

Multiple SC Doses

PF-06342674 Dose Dbiological

Multiple SC Doses